Surgery Partners (NASDAQ:SGRY) Stock Price Up 5.7%

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) traded up 5.7% during trading on Monday . The stock traded as high as $26.45 and last traded at $25.92. 318,638 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 880,022 shares. The stock had previously closed at $24.53.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $43.00 price target on shares of Surgery Partners in a research note on Wednesday, April 10th. Barclays initiated coverage on Surgery Partners in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $35.00 price target on the stock. Benchmark reaffirmed a “buy” rating and set a $50.00 price objective on shares of Surgery Partners in a research report on Wednesday, May 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $49.00 target price on shares of Surgery Partners in a report on Thursday, February 29th. Finally, Citigroup cut their price target on shares of Surgery Partners from $42.00 to $38.00 and set a “buy” rating for the company in a report on Wednesday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.13.

Surgery Partners Price Performance

The business’s 50-day simple moving average is $27.46 and its two-hundred day simple moving average is $29.81. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of -270.70, a price-to-earnings-growth ratio of 2.24 and a beta of 2.75. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.71 and a quick ratio of 1.57.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $735.40 million for the quarter, compared to analyst estimates of $741.93 million. Surgery Partners had a positive return on equity of 3.65% and a negative net margin of 0.43%. Surgery Partners’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS. Research analysts expect that Surgery Partners, Inc. will post 0.78 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO David T. Doherty sold 1,020 shares of Surgery Partners stock in a transaction on Monday, February 12th. The stock was sold at an average price of $34.93, for a total transaction of $35,628.60. Following the sale, the chief financial officer now directly owns 74,209 shares in the company, valued at approximately $2,592,120.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Surgery Partners news, insider Bradley R. Owens sold 1,040 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.22, for a total transaction of $36,628.80. Following the sale, the insider now owns 73,149 shares in the company, valued at $2,576,307.78. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David T. Doherty sold 1,020 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $34.93, for a total transaction of $35,628.60. Following the completion of the sale, the chief financial officer now owns 74,209 shares in the company, valued at $2,592,120.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,664 shares of company stock valued at $477,225. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors have recently made changes to their positions in the business. Mesirow Institutional Investment Management Inc. increased its position in shares of Surgery Partners by 12.4% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 3,388 shares of the company’s stock valued at $108,000 after acquiring an additional 373 shares during the period. Amalgamated Bank raised its holdings in shares of Surgery Partners by 7.6% during the third quarter. Amalgamated Bank now owns 9,948 shares of the company’s stock valued at $291,000 after acquiring an additional 701 shares in the last quarter. Raymond James & Associates boosted its holdings in Surgery Partners by 1.2% in the third quarter. Raymond James & Associates now owns 61,188 shares of the company’s stock valued at $1,790,000 after acquiring an additional 736 shares in the last quarter. Natixis Advisors L.P. increased its position in shares of Surgery Partners by 8.6% during the fourth quarter. Natixis Advisors L.P. now owns 11,735 shares of the company’s stock valued at $375,000 after buying an additional 934 shares during the period. Finally, ProShare Advisors LLC raised its stake in Surgery Partners by 7.8% in the first quarter. ProShare Advisors LLC now owns 13,588 shares of the company’s stock worth $405,000 after buying an additional 986 shares in the last quarter.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.